Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: naked DNA.

Y Ilan1

  • 1Liver Unit, Division of Medicine, Hadassah University Hospital, Jerusalem, Israel. ILAN@hadassah.org.il

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.

Clinical and experimental immunology·2018
Same author

Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift.

BMC gastroenterology·2017
Same author

Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression.

Alimentary pharmacology & therapeutics·2016
Same author

Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

Leukemia & lymphoma·2016
Same author

Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.

Clinical and experimental immunology·2015
Same author

Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial.

Journal of viral hepatitis·2014
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Vical and Merck are developing novel vaccines for hepatitis B using patented naked DNA technology. This approach involves injecting DNA into muscle to stimulate a strong immune response for protection.

Area of Science:

  • Biotechnology
  • Immunology
  • Vaccinology

Background:

  • Hepatitis B remains a significant global health concern.
  • Current vaccines have limitations, necessitating novel approaches.
  • Vical's patented naked DNA technology offers a new platform for vaccine development.

Purpose of the Study:

  • To investigate the efficacy of naked DNA technology for hepatitis B vaccine development.
  • To explore both therapeutic and prophylactic applications of this novel vaccine strategy.

Main Methods:

  • Utilizing Vical's patented naked DNA technology.
  • Direct injection of exogenous cDNA into muscle tissue.
  • Monitoring protein expression and immune response.

Main Results:

Related Experiment Videos

  • Demonstrated protein expression following cDNA injection.
  • Observed a strong immune response in preclinical models.
  • Indicated potential for protective immunity against hepatitis B.

Conclusions:

  • Naked DNA technology shows promise for hepatitis B vaccine development.
  • The collaboration between Vical and Merck aims to advance these vaccines.
  • Further research and clinical trials are warranted to confirm efficacy and safety.